Something for Nothing

References

1. 1.↵
   1. Moldenhauer J.

   1. Sutton S.

   The Sterility Tests. In Rapid Sterility Testing; Moldenhauer J., Ed.; PDA/DHI: Bethesda, MD, 2011; pp 7–24.
2. 2.↵
   Federal Standard 209: Clean Room and Work Station Requirements, Controlled Environment, 1963.
3. 3.↵
   World Health Organization. Technical Report Series No. 530: Annex 4, General Requirements for the Sterility of Biological Substances. Part A, Section 2. WHO: Geneva, 1973.
4. 4.↵
   1. Knudsen L. F.

   Sample Size of Parenteral Solutions for Sterility Testing. J. Am. Pharm. Assoc., Sci. Ed. 1949, 38 (6), 332–337.

   OpenUrl
5. 5.↵
   1. Bryce D. M.

   Tests for the Sterility of Pharmaceutical Preparations; the Design and Interpretation of Sterility Tests. J. Pharm. Pharmacol. 2011, 8 (1), 561–572.

   OpenUrl
6. 6.↵
   1. Bowman F. W.

   The Sterility Testing of Pharmaceuticals. J. Pharm. Sci. 1969, 58 (11), 1301–1308.

   OpenUrlPubMed
7. 7.↵
   U.S. Food and Drug Administration, Guideline on Sterile Drug Products Produced by Aseptic Processing. Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 1987.
8. 8.↵
   European Medicines Agency. Annex 1, Sterile Medicinal Products. EMA: London, 2001.
9. 9.↵
   U.S. Food and Drug Administration, Guideline on Sterile Drug Products Produced by Aseptic Processing. Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 2004.
10. 10.↵
    European Medicines Agency. Annex 1, Sterile Medicinal Products draft revision, EMA: London, 2017.
11. 11.↵
    USP <71> Sterility Tests. Pharmacopeial Forum 2008, 34 (6), 1418–1425.

    OpenUrl
12. 12.↵
    Department of Health and Social Services. Guide to Good Manufacturing Practices. HMSO, 1983.
13. 13.↵
    1. Agalloco J.

    Personal recollection, 1984.
14. 14.↵
    European Medicines Agency. Annex 1, Sterile Medicinal Products draft revision, EMA: London, 2020.
15. 15.↵
    World Health Organization. WHO/BS/73.1062: Sterility and Sterility Testing of Pharmaceutical Preparations and Biological Substances. WHO: Geneva, 1973.
16. 16.↵
    1. Akers J.,
    2. Agalloco J.

    Environmental Monitoring: Myths and Misapplications. PDA J. Pharm. Sci. Technol. 2001, 55 (3), 176–184.

    OpenUrlFREE Full Text
17. 17.↵
    1. Madsen R.,
    2. Agalloco J.

    Unknown and Unknowable. Pharm. Technol. 2019, 2019 (1), 4–9.

    OpenUrl
18. 18.↵
    1. Agalloco J.,
    2. Akers J.

    The Myth Called Sterility. Pharm. Technol. 2010, 34 (3), S44–S45.

    OpenUrl
19. 19.↵
    USP <1211> Sterility Assurance. Pharmacopeial Forum 2020, 43 (5), 101–125.

    OpenUrl
20. 20.↵
    EMA, Annex 1, Sterile Medicinal Products, 2022.
21. 21.↵
    1. Akers J.,
    2. Agalloco J.,
    3. Madsen R.

    What is Advanced Aseptic Processing? Pharm. Manuf. 2006, 4 (2), 25–27.

    OpenUrl
22. 22.↵
    Parenteral Drug Association Inc. Process Simulation Testing for Sterile Bulk Pharmaceutical Chemicals. PDA Technical Report No. 28, Revised. PDA J. Pharm. Sci. Technol. 2006, 60 (Suppl S-2), 1–22.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Agalloco J.

    Closed Systems and Environmental Control: Application of Risk Based Design. Am. Pharm. Rev. 2004, 7 (4), 26–29.

    OpenUrl
24. 24.↵
    1. Agalloco J.

    Straight Talk on Closed Systems. BioPharm Int. 2020, 20 (5), 32–36.

    OpenUrl